Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Dementia Clinical Trials

A listing of Dementia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (1048) clinical trials

Clinical research study of an investigational drug that may help slow or stop memory loss in people with early stages of Alzheimer's disease.  

Phase

Clinical research study of an investigational medication for the treatment of agitation in people with dementia of Alzheimer's type.  

Phase

The purpose of the study is to identify sleep and brain wave markers of Alzheimer’s disease before any memory problems.   There are two study visits: The first visit will last 3 to 4 hours. The second visit is an overnight visit (18-hours).   Participation includes a lumbar puncture, cognitive ...

Phase N/A

This is a randomized, double-blind, placebo-controlled study that will assess the efficacy, safety, and tolerability of 2 dose levels of COR388 HCl in subjects with probable AD dementia according to the National Institute on Aging-Alzheimer’s Association (NIA-AA) criteria (McKhann 2011).  

Phase

This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD. All participants must show evidence of beta-amyloid pathology. Eligible participants will be randomized 1:1 to receive either subcutaneous (SC) injection of gantenerumab or placebo. The ...

Phase

Multi-center, randomized, double-blind, parallel-group,placebo-controlled study to evaluate the safety and tolerability, efficacy, and PK of 60 mg and 90 mg AD-35 administered QD during 6 months of double-blind treatment followed by a second 6 months of open-label treatment to subjects with mild to moderate AD.

Phase N/A

Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease  

Phase N/A

A double-blinded, randomized, placebo-controlled study will be performed to evaluate the efficacy and safety of treating AR1001 in patients with mild to moderate Alzheimer's disease for 26 weeks  

Phase N/A

Preclinical models suggest that riluzole, the active metabolite of BHV-4157, may protect from AD-related pathology and cognitive dysfunction. Titrated dose of BHV-4157 to 280 mg, or placebo, taken orally once daily. Duration of treatment is 48 weeks. There is also a screening period of up to 42 days; and a ...

Phase

A double-blinded, randomized, placebo-controlled study will be performed to evaluate the efficacy and safety of treating AR1001 in patients with mild to moderate Alzheimer's disease for 26 weeks.

Phase N/A